Cue Biopharma Q1 net loss $12.3M; announces BI collaboration for CUE-501 and $20M capital raise

Cue Biopharma, Inc.

2025-Q1 EPS reported -$0.17 vs consensus -$4.65 ▲ beat (+96.3%)

Net loss $12.3M ($0.17 EPS) vs $12.3M ($0.25) YoY; revenue $0.4M down from $1.7M.
Announced Boehringer Ingelheim collaboration for CUE-501: $12M upfront + up to $345M milestones.
Raised ~$20M gross in follow-on capital raise; received $12M BI upfront in April 2025.
Regained worldwide rights to lead autoimmune program CUE-401; virtual event May 15 with KOLs.
R&D spend $8.5M vs $10.2M YoY; G&A flat at $4.2M; cash $13.1M at Mar 31.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.